Informed Consent Form Sample for Research

INSTITUTIONAL RESEARCH INFORMED CONSENT & AUTHORIZATION AGREEMENT

DOCUMENT CONTROL

• Effective Date: [Effective Date]
• Document Version: 4.2-CORP
• Jurisdiction / Scope: [State/Country Jurisdiction] | Human Subject Research Protocol #[Protocol Number]

---

OFFICIAL NOTICE & LEGAL DISCLAIMER

Disclaimer: This document is a production-ready legal and operational template designed for human subject research. It must be reviewed, customized, and approved by institutional legal counsel and the applicable Institutional Review Board (IRB) or Ethics Committee prior to deployment. Execution of this document establishes a legal and ethical contract between the researcher and the participant; failure to comply with its terms may result in regulatory non-compliance, legal liability, and immediate termination of the research protocol.

---

1. PARTIES & DEFINITIONS

This Informed Consent and Authorization Agreement ("Agreement") is entered into as of [Date] ("Effective Date"), by and between:

• Principal Investigator (PI) / Research Entity: [Name of Principal Investigator / Institution / Company Name], having its principal place of business at [Physical Address] ("Researcher"), and
• Research Participant: [Participant Full Legal Name], residing at [Participant Address], born on [Date of Birth] ("Participant" or "You").

Definitions:

• "Study" refers to the research protocol titled [Full Title of Research Protocol].
• "Data" includes all personal information, clinical metrics, biological samples, survey responses, and digital telemetry collected pursuant to the Study.
• "Sponsor" refers to [Name of Funding Body or Corporate Sponsor, or "N/A" if none].

---

2. OPERATIVE CLAUSES & TERMS

1. Purpose of the Study

You are invited to participate in the Study referenced above. The purpose of this research is to [Provide a precise, concise scientific/commercial objective of the research]. Your participation is entirely voluntary.

2. Study Procedures & Participant Commitments

If you agree to participate, you will be required to perform the following actions:

• [Detail Step 1, e.g., Attend X clinical visits at Location Y over Z weeks.]
• [Detail Step 2, e.g., Complete daily digital questionnaires regarding symptoms.]
• [Detail Step 3, e.g., Provide biological specimens, including blood draws not exceeding X mL.] Total estimated time commitment for your participation is [Number] hours across [Number] weeks/months.

3. Risks, Discomforts, and Inconveniences

Participation in this Study may entail certain risks, including but not limited to:

• Physical Risks: [e.g., Mild bruising, soreness from blood draws, temporary fatigue.]
• Psychological/Privacy Risks: [e.g., Potential anxiety from questionnaires, rare risk of data breach despite robust encryption.]
• Unforeseen Risks: The Study may involve risks that are currently unpredictable. The Researcher will promptly notify you of any new findings that may affect your willingness to continue participating.

4. Potential Benefits

• Direct Benefits: You may [state direct medical or personal benefit, or explicitly state: "receive no direct medical benefit from participating in this Study."].
• Indirect/Societal Benefits: Data gathered from this Study may contribute to the general scientific understanding of [Field of Study] and assist in the future development of [Product/Therapy/Process].

5. Confidentiality, Data Protection, and HIPAA Authorization

Your identity and the Data collected from you will be handled with strict confidentiality in compliance with applicable data protection laws (including HIPAA, GDPR, and local statutes).

• Access to Records: Your records may be reviewed by the Researcher, the [Name of Institutional Review Board / Ethics Committee], and regulatory authorities ([e.g., FDA]).
• Data De-identification: Your Data may be de-identified (stripping all direct identifiers such as name, address, and DOB). Once de-identified, this Data may be used for future research or commercialized without your additional explicit consent.
• Publication: Any reports or publications resulting from this Study will use aggregated or anonymized data only; your identity will not be disclosed in any public forum.

6. Compensation and Costs

• Compensation: You will receive [$Amount / "No compensation"] for your time and completion of the Study milestones, disbursed via [Method of Payment] upon [Condition, e.g., completion of all protocol visits].
• Costs: You or your insurance carrier will not be billed for any procedures, tests, or devices that are exclusively required for this Study. You remain responsible for standard medical care costs outside the scope of this protocol.

7. Voluntary Participation & Right to Withdraw

Your participation in this Study is strictly voluntary. You may refuse to participate, or you may withdraw your consent and discontinue participation at any time without penalty, loss of benefits, or adverse impact on your medical care or professional standing. To withdraw, notify the Researcher in writing at [Contact Email/Address].

8. Investigator-Initiated Termination

The Researcher, Sponsor, or IRB reserves the right to terminate your participation in the Study at any time without your consent if:

• You fail to follow the instructions of the research staff.
• Continuing the Study would be detrimental to your health or safety.
• The entire research protocol is canceled or suspended.

9. Contact Information and Queries

If you have any questions, concerns, or complaints about the Study, or if you sustain a research-related injury, contact:

• Principal Investigator: [PI Name] at [Phone Number] or [Email Address]
• Institutional Review Board (IRB): [IRB Name/Office] at [IRB Phone Number] or [IRB Email]

---

3. SIGNATURES & ACKNOWLEDGMENT BLOCK

By signing below, you acknowledge that you have read and understood this entire Informed Consent and Authorization Agreement. All your questions have been answered to your satisfaction. You voluntarily agree to participate in the Study and authorize the collection, use, and disclosure of your Data as described herein. You will receive a fully executed copy of this document for your records.

RESEARCH PARTICIPANT

____________________________________________________     ________________________
Signature of Participant                                 Date (MM/DD/YYYY)

____________________________________________________
Printed Name of Participant

LEGALLY AUTHORIZED REPRESENTATIVE (If Applicable)

(Required only if participant is a minor or legally incapacitated)

____________________________________________________     ________________________
Signature of Legal Representative                        Date (MM/DD/YYYY)

____________________________________________________     ________________________
Printed Name of Legal Representative                     Relationship to Participant

PRINCIPAL INVESTIGATOR / DESIGNATED OBTAINING CONSENT

I certify that I have explained the nature and purpose of this research Study to the participant, outlined the potential risks and benefits, and answered all questions to the best of my ability.

____________________________________________________     ________________________
Signature of Person Obtaining Consent                    Date (MM/DD/YYYY)

____________________________________________________
Printed Name and Title of Person Obtaining Consent

---

4. STEP-BY-STEP EXECUTION GUIDE

1. Customization: Replace all bracketed placeholder text (e.g., [...]) with protocol-specific data. Ensure alignment with the protocol approved by your institutional IRB/Ethics Committee.
2. Review & Approval: Submit the populated draft to your legal counsel and IRB for formal review. Do not alter core liability or confidentiality clauses without legal sign-off.
3. Execution: Ensure the Participant (or their Legally Authorized Representative) and the designated study staff member sign and date the document prior to the initiation of any research-related procedures.
4. Archival & Compliance: Provide a signed copy to the participant immediately. Store the original executed document in a secure, HIPAA/GDPR-compliant regulatory binder or electronic trial master file (eTMF) for the retention period mandated by institutional policy (typically 6–10 years post-study completion).